Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10604	7,8-Didehydrocimigenol
BP10604	7,8-Didehydrocimigenol can be used for the treatment of cardiovascular disorders such as atherosclerosis. It upregulates PPAR-γ in EC inhibits NF-kB activity of TNF-α-activated EC which leads to selective inhibition of VCAM-1 expression.
BP10645	7alpha,15-Dihydroxydehydroabietic acid
BP10645	7alpha,15-Dihydroxydehydroabietic acid may exhibit significant cytotoxic activity.
BP10462	8alpha-Hydroxyhirsutinolide
BP10462	8alpha-Hydroxyhirsutinolide shows anti-inflammatory activity, it inhibits TNF-α-induced NF-ÎºB activity with the IC(50) value of 1.9 uM.
BP10501	9-dihydro-13-acetylbaccatin III
BP10501	9-Dihydro-13-acetylbaccatin III is an apoptosis inducer. It shows cytotoxicity against the MCF7 cell line and drug-resistant cell line MCF7-ADR.
BP10057	9-ING-41
BP10057	9-ING-41 is a glycogen synthase kinase-3 inhibitor.
BP10721	9-O-Feruloyl-5,5'-dimethoxylariciresinol
BP10721	(+)-9'-O-trans-feruloyl-5,5'-dimethoxylariciresinol may have anti-allergic inflammatory effect, it can inhibit release of histamine from mast cells. It shows cytotoxicity against a small panel of human tumor cell lines, with ED50 values of 9.86 to approximately 12.68 microg/ml.
BP10536	A 419259 trihydrochloride
BP10536	A 419259 trihydrochloride is an Src family kinases inhibitor (IC50s: 9 nM, 3 nM and 3 nM for Src, Lck and Lyn).
BP10280	A-1155463
BP10280	A-1155463, a highly potent and selective BCL-XL inhibitor, shows picomolar binding affinity to BCL-XL, and >1000-fold weaker binding to BCL-2 and related proteins BCL-W(Ki=19 nM) and MCL-1(Ki>440 nM).
BP10723	A-1210477
BP10723	A-1210477 is an effective and specific MCL-1 and Bcl-2 inhibitor (Ki/IC50: 0.454/26.2 nM).
BP10527	A-1331852
BP10527	A-1331852 is a potent and selectiveBCL-XL inhibitor and may be useful in the treatment of cancer, immune and autoimmune diseases.
BP10422	Abacavir
BP10422	Abacavir is a nucleoside reverse transcriptase inhibitor analog of guanosine. This agent decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.
BP10857	Abacavir sulfate
BP10857	Abacavir, a nucleoside analogue, effectively utilize its antiviral activity
BP10688	Abrocitinib
BP10688	Abrocitinib (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).
BP10491	Acalabrutinib
BP10491	Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
BP10739	Ac-DEVD-AMC
BP10739	Ac-DEVD-AMC is the substrate of Caspase-3 .
BP10738	Ac-DEVD-CHO
BP10738	Ac-DEVD-CHO is a selective Caspase-3 inhibitor (Ki: 230 pM).
BP10845	Actein
BP10845	Actein has a stimulatory effect on osteoblastic bone formation or has potential activity against osteoporosis, it also can prevent oxidative damage to osteoblasts in osteoporotic patients. Actein's ability to pathways involved in lipid disorders and carcinogenesis may make it a new agent for preventing and treating these major disorders, it has been shown to inhibit the proliferation of human breast cancer cells, by altering the activity of the ER IP3 receptor and Na,K-ATPase, inducing calcium release and modulating the NF-kB and MEK pathways.
BP10449	AD80
BP10449	AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
BP10365	Afatinib D6
BP10365	Afatinib D6 (BIBW 2992 D6) is a deuterium-labeled Afatinib. Afatinib is an irreversible EGFR family inhibitor.
BP10184	Aflatoxin G1
BP10184	Aflatoxin G1 (AFG1 ), a member of the AF family with cytotoxic and carcinogenic properties, could cause DNA damage in alveolar type II (AT-II) cells and induce lung adenocarcinoma.